CONMED reports Q3 2026 results and raises FY 2026 adjusted EPS guidance
CONMED Corp. posted third‑quarter 2026 net revenue of $335.6 million, a 0.7% year‑over‑year decline on a reported basis but a 6.7% increase on an organic constant‑currency basis. Adjusted diluted EPS was $1.04, beating estimates, while GAAP diluted EPS rose 613.7% to $0.66. The company narrowed full‑year net‑sales guidance to $1.36‑$1.37 billion and lifted adjusted EPS guidance to $4.54‑$4.61 per share for 2026, citing stronger performance of its AirSeal, Buffalo Filter and BioBrace platforms.
Why it matters
The higher EPS outlook, announced in the 8‑K filing, raises investors’ expectations for profitability in 2026 (the company says the new range reflects the strong Q3 execution). The narrowed revenue range tightens the market’s view of top‑line growth, which may affect valuation models and analyst forecasts.
Key facts
- 1Third‑quarter 2026 net revenue was $335.6 million, down 0.7% year‑over‑year on a reported basis. sec.gov
- 2Excluding strategic GI product exits, net sales grew 6.7% on an organic constant‑currency basis. sec.gov
- 3GAAP diluted earnings per share were $0.66, up 613.7% versus the prior year. sec.gov
- 4Adjusted diluted earnings per share were $1.04, down 3.2% year‑over‑year. sec.gov
- 5Full‑year 2026 net‑sales guidance was revised to $1.360 billion‑$1.366 billion. sec.gov
- 6Adjusted EPS guidance for 2026 was raised to $4.54‑$4.61 per share. sec.gov
Summary written by AlphAI AI Desk from 17 of 17 sources. Not investment advice. Figures are as stated by the linked sources.